Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast

BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 28, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021 .